Schedule I - Condensed Financial Information - Statements of Cash Flows (Details) - USD ($)
$ in Thousands |
9 Months Ended |
12 Months Ended |
Sep. 30, 2021 |
Sep. 30, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
| Cash flows from operating activities |
|
|
|
|
| Net loss |
$ (400,555)
|
$ (10,001)
|
$ (136,392)
|
$ (363,737)
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
| Amortization of notes discount |
|
|
21,084
|
15,807
|
| Stock-based compensation expense |
132,542
|
4,949
|
7,078
|
3,301
|
| Paid in kind interest |
0
|
18,769
|
28,334
|
11,633
|
| Change in fair value of warrants |
(66,146)
|
31,903
|
80,110
|
2,836
|
| Change in derivative liabilities |
0
|
(87,475)
|
(93,751)
|
138,561
|
| Amortization of warrants |
|
|
218
|
73
|
| Amortization of debt issuance costs |
|
|
34
|
506
|
| Changes in operating assets and liabilities: |
|
|
|
|
| Other assets |
(10,261)
|
496
|
(5,470)
|
(274)
|
| Accounts payable and accrued expenses |
1,386
|
5,937
|
10,845
|
6,298
|
| Accrued salaries and benefits |
9,458
|
662
|
186
|
(2,235)
|
| Net cash used in operating activities |
(202,150)
|
(58,594)
|
(118,498)
|
(159,875)
|
| Cash flows from investing activities |
|
|
|
|
| Net cash provided by (used in) investing activities |
(328,956)
|
69,847
|
137,404
|
(181,908)
|
| Cash flows from financing activities |
|
|
|
|
| Deferred financing costs |
0
|
(108)
|
(98)
|
(363)
|
| Payment of notes payable principal |
(30,925)
|
(13,868)
|
(18,752)
|
(9,670)
|
| Issuance of common stock, net of early exercise liability |
5,547
|
954
|
1,748
|
601
|
| Buyback and subsequent cancellation of common stock |
(147)
|
0
|
(957)
|
0
|
| Net cash provided by financing activities |
641,022
|
10,881
|
5,844
|
333,978
|
| Net increase (decrease) in cash and cash equivalents |
109,916
|
22,134
|
24,750
|
(7,805)
|
| Cash and cash equivalents, beginning of year |
92,348
|
67,598
|
67,598
|
75,403
|
| Cash and cash equivalents, end of year |
202,264
|
89,732
|
92,348
|
67,598
|
| Parent Company |
|
|
|
|
| Cash flows from operating activities |
|
|
|
|
| Net loss |
|
|
(136,392)
|
(363,737)
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
| Amortization of notes discount |
|
|
21,084
|
15,807
|
| Stock-based compensation expense |
|
|
7,078
|
3,301
|
| Paid in kind interest |
|
|
28,334
|
11,633
|
| Change in fair value of warrants |
|
|
80,110
|
2,836
|
| Change in derivative liabilities |
|
|
(93,751)
|
138,561
|
| Amortization of warrants |
|
|
218
|
73
|
| Amortization of debt issuance costs |
|
|
34
|
506
|
| Changes in operating assets and liabilities: |
|
|
|
|
| Other assets |
|
|
214
|
(391)
|
| Accounts payable and accrued expenses |
|
|
7,669
|
5,728
|
| Accrued salaries and benefits |
|
|
229
|
(169)
|
| Intercompany interest receivable |
|
|
(1,208)
|
(1,200)
|
| Intercompany payable |
|
|
23,158
|
(23,921)
|
| Net cash used in operating activities |
|
|
(63,223)
|
(210,973)
|
| Cash flows from investing activities |
|
|
|
|
| Investments in consolidated subsidiaries |
|
|
82,047
|
(154,469)
|
| Net cash provided by (used in) investing activities |
|
|
82,047
|
(154,469)
|
| Cash flows from financing activities |
|
|
|
|
| Proceeds from issuance of convertible securities |
|
|
0
|
343,410
|
| Deferred financing costs |
|
|
0
|
(363)
|
| Payment of notes payable principal |
|
|
(18,752)
|
(9,670)
|
| Issuance of common stock, net of early exercise liability |
|
|
1,748
|
601
|
| Buyback and subsequent cancellation of common stock |
|
|
(957)
|
0
|
| Net cash provided by financing activities |
|
|
(17,961)
|
333,978
|
| Net increase (decrease) in cash and cash equivalents |
|
|
863
|
(31,464)
|
| Cash and cash equivalents, beginning of year |
$ 5,432
|
$ 4,569
|
4,569
|
36,033
|
| Cash and cash equivalents, end of year |
|
|
$ 5,432
|
$ 4,569
|